Table 1.
Summary of short-term randomised controlled trials of risperidone in disruptive behaviour disorders in children and adolescents 5 years and above
| Reference | Sample (age) IQ |
Duration | Dose (mg/day) | Primary outcome Mean change (SD) placebo/risperidone (p) Effect size |
|---|---|---|---|---|
| Findling 2000 | N = 20 (5–12) | 10 weeks | 0.75–1.5 | RAAPP |
| IQ > 70 | −0.16 (0.54)/−1.65 (0.40) (p = 0.03) | |||
| Buitelaar 2001 | N = 38 (12–18) | 6 weeks | 2.9 | CGI-S |
| IQ 60–90 | (p < 0.01) | |||
| Van Bellinghen 2001 | N = 13 (6–18) | 4 weeks | 1.2 | ABC irritability (not prespecified) |
| IQ 45–85 | 0.1 (9.4)/−10.8 (6.05) (p < 0.05) | |||
| Aman 2002 | N = 118 (5–12) | 6 weeks | 1.16 | NCBRF-CP |
| IQ 34–84 | −6.2 (11.2)/−15.2 (10.6) (p < 0.001) | |||
| −0.82 | ||||
| Snyder 2002 | N = 110 (5–12) | 6 weeks | 0.98 | NCBRF-CP |
| IQ 36–84 | −6.8/−15.8 (p < 0.01) | |||
| −0.73 | ||||
| Reyes 2006 | N = 335 (5–17) | 6 months | <50 kg 0.81 | Time to symptom recurrencea |
| 216 with IQ > 84 | >50 kg 1.22 | Symptom recurrence in 25 %: 37 versus 119 days (p < 0.001) | ||
| 119 with IQ < 84 | ||||
| Armenteros 2007 | N = 25 (7–12) | 28 days | 1.08 | CAS-P and CAS-T ≥ 30 % change |
| IQ > or = 75 | CAS-P total: 77 %/100 % (p < 0.5) | |||
| All with ADHD | CAS-T total: 54 versus 27 % (NS) | |||
| No differences in mean CAS scores. |
RAAPP rating of aggression against people and/or property scale, CGI-S Clinical Global Impression-Severity, NCBRF-CP Nisonger Child Behaviour Rating Form conduct problem subscale, CAS-P Children’s Aggression Scale-Parent, CAS-T Children’s Aggression Scale-Teacher, NS non significant
aDeterioration of two points or more on the Clinical Global Impression-Severity or seven points of more on the conduct problems subscale